AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Accuray (ARAY)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

2.23

0.01 (0.45%)

At close: Jan 28, 2025, 2:11 PM

undefined% (undefined)

Bid	2.23
Market Cap	224.76M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-0.17
PE Ratio (ttm)	-13.15
Forward PE	n/a
Analyst	Buy

Ask	2.24
Volume	212,787
Avg. Volume (20D)	674,966
Open	2.23
Previous Close	2.22
Day's Range	2.20 - 2.29
52-Week Range	1.40 - 2.95
Beta	undefined

About ARAY

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, China, and rest of the Asia Pacific region. It offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and m...

[Show more]

Industry Medical - Specialties

Sector Healthcare

IPO Date Feb 8, 2007

Employees 987

Stock Exchange NASDAQ

Ticker Symbol ARAY

Website https://www.accuray.com

Analyst Forecast

According to 1 analyst ratings, the average rating for ARAY stock is "Buy." The 12-month stock price forecast is $9, which is an increase of 302.68% from the latest price.

Buy 100.00%

Hold 0.00%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Accuray is scheduled to release its earnings on Feb 5, 2025, after market closes.
Analysts project revenue of $110.36M, reflecting a 2.91% YoY growth and earnings per share of -0.04, making a -60.00% decrease YoY.

Why Price Moved

5 months ago

+51.75%

Accuray shares are trading higher after the compan... Unlock content with Pro Subscription

5 months ago

-1.38%

Accuray shares are trading higher after the company reported better-than-expected Q4 sales results.

News

1 week ago · zacks.com

Accuray (ARAY) Shows Fast-paced Momentum But Is Still a Bargain Stock

Accuray (ARAY) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that ma...

1 week ago · zacks.com

ARAY Stock Gains as China Approves Latest Radiation Therapy Solutions

Accuray announces the approval of the Chinese NMPA for its latest radiation therapy solutions.

2 weeks ago · zacks.com

Here's Why You Should Add Accuray Stock to Your Portfolio Now

ARAY's solid product demand and revenue growth raise optimism about the stock.

2 weeks ago · seekingalpha.com

Accuray - There's Value If Linac Sales Accelerate, But That's A Big 'If'

Impressive revenue growth remains elusive for Accuray despite the potential in China, and there are ongoing challenges with profitability, competition, and market scale. The last quarter's results sho...

3 weeks ago · zacks.com

Here Is Why Bargain Hunters Would Love Fast-paced Mover Accuray (ARAY)

If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Accuray (ARAY) could be a great choice. It is one of the several stocks that passed ...

4 weeks ago · zacks.com

5 Beaten-Down MedTech Stocks Set to Rebound in 2025

Investors may want to take a closer look at discounted stocks, such as MCK, HAE, ARAY, LIVN and PBH, in the present market landscape.

1 month ago · zacks.com

ARAY Stock Falls Despite Positive Data of CyberKnife in Treating BSM

Accuray announces positive study data for its CyberKnife System in treating brainstem metastases.

1 month ago · zacks.com

Looking for a Fast-paced Momentum Stock at a Bargain? Consider Accuray (ARAY)

1 month ago · zacks.com

Here's Why You Should Add Accuray Stock in Your Portfolio Now

ARAY's solid product demand and revenue growth raise optimism about the stock.

2 months ago · zacks.com

Accuray Q1 Earnings Meet Estimates, Sales Beat, Gross Margin Shrinks

ARAY's first-quarter fiscal 2025 earnings meet estimates. Both the top and bottom lines deteriorate year over year.

2 months ago · seekingalpha.com

Accuray Incorporated (ARAY) Q1 2025 Earnings Call Transcript

2 months ago · zacks.com

Accuray (ARAY) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

The headline numbers for Accuray (ARAY) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street esti...

2 months ago · zacks.com

Accuray (ARAY) Reports Q1 Loss, Tops Revenue Estimates

Accuray (ARAY) came out with a quarterly loss of $0.04 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.03 per share a year ago.